Tebaniklin
 | |
| IUPAC ime | |
|---|---|
5-([(2R)-Azetidin-2-il]metoksi)-2-hloropiridin | |
| Identifikatori | |
| CAS broj | 198283-73-7  |
| ATC kod | none |
| PubChem | CID 3075702 |
| UNII | 9KX8NKV538 |
| Hemijski podaci | |
| Formula | C9H11ClN2O |
| Molarna masa | 198,649 |
| |
Tebaniklin (Ebanicline, ABT-594) je lek koji je razvilo preduzeće Abbott. On deluje kao parcijalni agonist neuronskih nikotinskih acetilholinskih receptora. Tebaniklin se vezuje za α3β4 i α4β2 receptore.[1] Ovaj lek je razvijen kao manje toksični analog epibatidina, koji ima oko 200x jače analgetskog dejstvo od morfina, ali je veoma toksičan.[2][3]
Reference
[уреди | уреди извор]- ^ Jain, K. K. (2004). „Modulators of nicotinic acetylcholine receptors as analgesics”. Current opinion in investigational drugs (London, England : 2000). 5 (1): 76—81. PMID 14983978.
- ^ Bannon, A. W.; Decker, M. W.; Holladay, M. W.; Curzon, P.; Donnelly-Roberts, D.; Puttfarcken, P. S.; Bitner, R. S.; Diaz, A.; Dickenson, A. H. (1998). „Broad-spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors”. Science. 279 (5347): 77—81. Bibcode:1998Sci...279...77B. PMID 9417028. doi:10.1126/science.279.5347.77.
- ^ Holladay, M.; Wasicak, J.; Lin, N.; He, Y.; Ryther, K.; Bannon, A.; Buckley, M.; Kim, D.; Decker, M. (1998). „Identification and initial structure-activity relationships of (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594), a potent, orally active, non-opiate analgesic agent acting via neuronal nicotinic acetylcholine receptors”. Journal of Medicinal Chemistry. 41 (4): 407—412. PMID 9484491. doi:10.1021/jm9706224.
Spoljašnje veze
[уреди | уреди извор]
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.
Cover photo is available under {{::mainImage.info.license.name || 'Unknown'}} license.
Cover photo is available under {{::mainImage.info.license.name || 'Unknown'}} license.
Credit:
(see original file).
